Effect of 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol hydrochloride (FTY 720) on immune liver injury in mice

Jing-Hua He, Hui-Na Zhang, Zhi-Bin Lin

Abstract

AIM: To investigate the protective effect against two immune liver injury models in mice by 2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol hydrochloride and its possible mechanisms in Con A-induced liver damage.

METHODS: Liver tissue or hepatocyte injury was monitored biochemically by measuring alanine aminotransferase (sALT) and aspartate aminotransferase (sAST) activity. Hematoxylin & eosin (HE) staining was used for histopathological examination. To evaluate the role of IFN-γ and IL-4 in the liver injury, serum levels of IFN-γ and IL-4 were determined using commercially available ELISA kit at 12 h after Con A challenge. We also determined FTY 720-induced spleen cell apoptosis by flow cytometry analysis or spleen cell proliferation test.

RESULTS: Different doses of FTY 720 treatment dramatically reduced circulating markers of hepatocyte injury in two kinds of immunological liver injury models. FTY 720 dramatically reduced the elevated serum IFN-γ and IL-4 levels after Con A injection. Effect of spleen cell supernatants treated with Con A or FTY 720 on hepatocytes showed that ALT activities in cultured hepatocyte supernatants treated with Con A treatment group increased markedly and FTY 720 could reduce this elevated ALT activities in FTY 720 treatment group. FTY 720 dose-dependently increased the percentage of apoptotic cells in T cells and inhibited splenocyte proliferation induced by Con A.

CONCLUSION: Pretreatment with FTY 720 was shown to produce protective effect on the immune liver injury in mice. The possible mechanism of FTY 720 on Con A-induced liver damage is that it could inhibit lymphocyte proliferation and induce lymphocyte apoptosis, resulting in the reduction of IL-4 or IFN-γ release, and subsequently protecting liver from being damaged by Con A.

INTRODUCTION

Acute liver injury is a common disease caused by hepatitis virus, alcohol, drugs, etc. Many medicines such as antiviral, immunomodulatory, auxiliary agents have been used to treat acute liver injury, but the therapeutic effects are not so satisfactory[1]. To prevent hepatocyte necrosis in acute stage of liver inflammation, immunosuppressants could be used. It has been reported that cyclosporine A and FK 506 have protective effects on experimentally-induced acute liver injury[2,3]. BCG-pretreatment plus lipopolysaccharide (LPS) or Con A-induced immune liver injury models are two established experimental immune liver injury models commonly used for the study of hepatoprotective medicines[4].

2-amino-2-[2-(4-octylphenyl) ethyl] propane-1,3-diol hydrochloride (FTY 720, C_{19}H_{26}N_{2}O_{2}HCl; molecular weight 343.94 Da), a novel immunosuppressive agent, is a synthetic structural analog of sphingosine related to the drug myriocin (ISP-1), which was isolated from culture filtrates of the ascomycete Isaria sinclairii. Ascomycetes are mycelial forms of Fungi Imperfecti, which are characterized by asexual spore phases. These organisms usually parasitize insects or plants[5]. FTY 720 has been shown to markedly prolong the survival time of rat skin and cardiac allografts[6]. FTY 720 is able to treat the experimental autoimmune thyroiditis in rats, autoimmune diabetes animal model, prostate cancer, and hepatic ischemia-reperfusion injury[7-10]. But, there has been no report about the effect of FTY 720 on immunological liver injury. This study was to evaluate the protective effect of FTY 720 as a new immunosuppressant on experimental immune acute liver injury.

MATERIALS AND METHODS

Animals

Male mice (albino Swiss) weighing 18-22 g, 6-8 wk old and male Wistar rats (weighing 200-250 g), were all obtained from the Department of Experimental Animals, Peking University Health Science Center, Beijing, China. Animals received humane care according to the criteria outline in the “Guide for the Care and Use of Laboratory Animals” made by the Chinese Academy of Sciences. Mice were maintained under controlled conditions (22 °C, 55% humidity, 12 h day/night cycle) and were fed with a standard laboratory chow until the experiments were completed.

Drugs and reagents

FTY 720 was supplied as dry powders by Hangzhou Sino-American Hua-Dong Pharmaceutical Co. Ltd and dissolved in physiological saline. BCG was purchased from Bioproducts, Inc., for diagnostic use. E. coli lipopolysaccharide (LPS) was purchased from Sigma-Aldrich, St Louis, MO, USA; ALT, AST testing kit (Chemical Reagents Co, Beijing); IFN-γ, IL-4 ELISA kit (Chemicon Co); MTT (Sigma-Aldrich, St Louis, MO, USA).
Con A challenge, serum samples from individual mice were injected Con A 15 mg/kg intravenously on the tenth day. At 12 h pretreatment groups, three doses of FTY 720 were administered: group 1: normal, group 2: Con A 15 mg/kg model control, group 3: Con A 15 mg/kg +FTY 720 1 mg/kg, group 4: Con A 15 mg/kg +FTY 720 6 mg/kg. In the pretreatment groups, three doses of FTY 720 were intravenously administered into mice once a day. On d 7, the animals in groups 2-5 were injected BCG (3 mg/mouse) intravenously. Another 14 d later, LPS (7.5 μg/mouse) was injected into the mice challenged with BCG. Mice were maintained on their respective drug administration during and after BCG and LPS injection. Twenty-four hours after LPS administration, serum samples from individual mice were obtained from the fundus oculi vein. Liver injury was monitored biochemically by measuring serum alanine aminotransferase (sALT) and aspartate aminotransferase (sAST) activities.

Effect of FTY 720 on Con A-induced liver injury

The mice were randomly divided into five groups, 10 mice in each. Group 1: normal, group 2: Con A 15 mg/kg model control, group 3: Con A 15 mg/kg +FTY 720 1 mg/kg, group 4: Con A 15 mg/kg +FTY 720 3 mg/kg, group 5: Con A 15 mg/kg +FTY 720 6 mg/kg. In the pretreatment groups, three doses of FTY 720 were intravenously administered into mice once a day, for 10 d. Then animals in groups 2-5 were injected Con A 15 mg/kg intravenously on the tenth day. At 12 h after Con A challenge, serum samples from individual mice were obtained from the fundus oculi vein for the determination of serum ALT and AST activities, as well as serum IFN-γ and IL-4 levels using commercially available ELISA kit. For histopathological evaluation, mice were sacrificed 12 h after Con A challenge. Liver tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin. Sections of 5 μm thickness were stained with hematoxylin & eosin (HE) for light-microscopic evaluation.

Effects of FTY720 conditioned medium with T lymphocytes (FTY720-T-CM) on isolated hepatocytes

Spleen cells from male Wistar rats were isolated by pressing the spleen through a steel grid into RPMI 1640 (GIBCO-BRL, Gaithersburg, MD, USA) medium. Red blood cells were lysed by 2-min incubation with 0.17 mol/L NH₄Cl at room temperature. Spleen cells were washed twice with RPMI 1640, and 10⁶ cells were incubated in RPMI 1640 containing 10% FCS for 48 h at 37 °C, in an atmosphere containing 50 mL/L CO₂ with: 1) medium alone; 2) Con A 5 mg/L; 3) Con A 5 mg/L+FTY 720 31.25 mg/L; 4) Con A 5 mg/L+FTY 720 62.5 mg/L; 5) Con A 5 mg/L+FTY 720 125 mg/L. The supernatants were collected 48 h later and stored at -20 °C.

Hepatocytes were isolated from adult male Wistar rats by collagenase perfusion as described previously[11]. The isolated hepatocytes were suspended in culture medium at 2×10⁶ cells/mL, seeded onto 6-well plastic dishes, and then cultured as monolayers in a CO₂ incubator (in a humidified atmosphere of 50 mL/L CO₂ in air) at 37 °C. The culture medium used was Dulbecco modified Eagle’s medium (DMEM) (GIBCO-BRL, Gaithersburg, MD, USA) containing 10% FCS, Hepes 15 mmol/L, penicillin 100 units/mL, streptomycin 0.1 g/L, insulin 0.01 g/L, sodium bicarbonate 3.7 g/L. After 12 h, the medium was replaced by fresh DMEM with supernatant of spleen cells (100 μL), and the cells were cultured for 24 h and then the ALT levels in the supernatants were determined.

Effect of FTY 720 on spleen lymphocyte proliferation induced by Con A

The spleen cell suspension (10⁶ cells/mL) was cultured in a 96-well culture plate in RPMI 1640 containing 10% FCS, Con A and different concentrations of FTY 720. After 68 h, 10 μL of stock MTT at a concentration of 5 mg/mL was added to each well, and the cells were further incubated at 37 °C for 4 h. The supernatant then was removed by centrifugation and 150 μL DMSO was added to each well. Following formazan solubilization, the absorbance of each well was measured using a microculture plate reader at wavelength of 570 nm.

Effect of FTY 720 on spleen lymphocyte apoptosis (flow cytometry analysis)

Spleen cells were cultured in 24-well plates at a density of 5×10⁶ in 1 mL of medium per well and were given different concentrations of FTY 720 in same volumes. Analysis of apoptosis was performed using annexin V kit (Baosai Co, Beijing). Briefly, one mL of cell suspension (10⁶ cells/mL) was incubated for 3 h under normal control or FTY 720-treated conditions and collected by centrifugation at 1000 r/min for 4 °C for 10 min. Pellets were washed twice with PBS and resuspended in 200 μL binding buffer with 10 μL annexin-V-FITC at room temperature for 10 min. PI (5 μL) was added and analysis was then performed using flow cytometry.

Statistical analysis

All statistical calculations were performed using SPSS10.0 statistical software; for all analyses, t test and one-way ANOVA were used to test for significance. P<0.05 was considered statistically significant.

RESULTS

Serum ALT and AST changes after pretreatment with FTY 720 in BCG+LPS-induced liver injury in mice

Serum ALT and AST activities increased dramatically compared with normal control mice 12 h after BCG+LPS injection. FTY 720 6 mg/kg dramatically reduced circulating markers of liver damage as shown in Table 1.

Table 1 Effect of FTY 720 on serum ALT and AST activities in BCG+LPS-induced liver injury (mean±SD)

| Group          | Number of mice | sALT Karman’s units/dL | sAST Karman’s units/dL |
|----------------|----------------|-------------------------|------------------------|
| Normal         | 10             | 19.65±11.87             | 108.00±22.37           |
| BCG (3 mg/mouse)| 10             | 234.24±143.17           | 254.71±101.45          |
| +LPS (7.5 μg/mouse) | 10             | 168.05±87.19            | 220.31±54.96           |
| BCG (3 mg/mouse) +FTY 720 1 mg/kg | 10 | 162.41±77.43            | 214.21±32.34           |
| +LPS (7.5 μg/mouse) +FTY 720 3 mg/kg | 10 | 119.41±77.45            | 183.00±46.29           |

*p<0.05 vs BCG (3 mg/mouse)+LPS (7.5 μg/mouse) model groups.

Serum ALT and AST changes after pretreatment with FTY 720 in Con A-induced liver injury in mice

Compared with normal control mice, serum ALT and AST activities increased dramatically 12 h after Con A challenge. FTY 720 6 mg/kg dramatically reduced circulating markers of liver injury as shown in Table 2.

Table 2 Alteration of serum cytokines after pretreatment with FTY720

Since both IFN-γ and IL-4 play critical roles in Con A-induced liver injury, we investigated the effect of FTY 720 on both serum levels in this model. Different doses of FTY 720 pretreatment dramatically reduced the elevated serum IFN-γ and IL-4 levels after Con A injection as shown in Table 3.
Table 2  Effect of FTY720 on serum ALT and AST activities in Con A-induced liver injury (mean±SD)

| Group                      | Number of mice | sALT Karman’s units/dL Mean±SE | sAST Karman’s units/dL Mean±SE |
|----------------------------|----------------|---------------------------------|---------------------------------|
| Normal                     | 10             | 52.79±4.43                      | 92.17±19.93                    |
| Con A 15 mg/kg             | 10             | 104.73±44.83                    | 120.34±28.25                   |
| Con A 15 mg/kg + FTY 720 1 mg/kg | 10   | 99.69±37.15                     | 116.27±22.47                   |
| Con A 15 mg/kg + FTY 720 3 mg/kg | 10   | 79.99±51.79                     | 110.63±26.26                   |
| Con A 15 mg/kg + FTY 720 6 mg/kg | 10   | 65.82±36.32 ±                   | 93.18±17.36                    |

′*P<0.05 vs Con A model group.

Table 3  Alteration of serum cytokines after treatment with FTY720 in Con A-induced liver injury (mean±SD)

| Group                      | Number of mice | IFN-γ (10^3 mg/L) Mean±SE | IL-4 (10^3 mg/L) Mean±SE |
|----------------------------|----------------|----------------------------|--------------------------|
| Normal                     | 10             | 0.25±0.03                  | 0.13±0.00                |
| Con A 15 mg/kg             | 10             | 0.93±0.49                  | 0.17±0.02                |
| Con A 15 mg/kg + FTY 720 1 mg/kg | 10   | 0.36±0.17                  | 0.15±0.01                |
| Con A 15 mg/kg + FTY 720 3 mg/kg | 10   | 0.33±0.10                  | 0.14±0.00                |
| Con A 15 mg/kg + FTY 720 6 mg/kg | 10   | 0.29±0.07                  | 0.03±0.01                |

′*P<0.05 vs Con A model group.

Effect of spleen cell supernatants on hepatocytes

Since the ALT activities were unchanged in supernatants of hepatocyte culture treated directly with Con A or FTY 720 (data not shown), the cultured spleen cell supernatants pretreated with Con A or Con A plus different concentrations of FTY 720 were added into the hepatocyte culture medium for 24 h. The results showed that ALT activities in cultured hepatocytes supernatants in Con A treatment group increased markedly and FTY 720 treatment could reduce the elevated ALT activities as shown in Figure 1.

Effect of FTY720 on spleen cell proliferation

Figure 2 shows that spleen cell proliferation markedly increased when treated with Con A, but a different dose of FTY 720 dramatically reduced the lymphocyte proliferation induced by Con A.

Effect of FTY 720 on spleen cell apoptosis

We also investigated the effect of FTY720 on T-lymphocyte apoptosis. A dose-dependent apoptosis was observed in T-lymphocytes as shown in Table 4 and Figure 3. FTY 720 dose-dependently increased the percentage of apoptotic cells in T-cells.

Table 4  Effect of FTY720 on spleen cell apoptosis

| Group                      | FTY 720 concentration % | Apoptotic cells % |
|----------------------------|--------------------------|-------------------|
| Normal                     |                          | 7.03              |
| FTY 720                    | 1.87 mg/L                | 7.55              |
| FTY 720                    | 3.75 mg/L                | 12.08             |
| FTY 720                    | 7.50 mg/L                | 25.46             |

Discussion

FTY 720 is a unique immunosuppressive agent that exerts its activity by inducing apoptosis in lymphocytes[12-14]. We conducted the present study to investigate the effect of FTY 720 on immunological liver injury, as well as its mechanism of action.
Viral hepatitis or autoimmune hepatitis is considered to be involved in the impairment of hepatocytes mainly mediated by T-cell immunity[10]. BCG+LPS or Con A could be used to induce immune liver injury models. T-cell-dependent specific liver injury in mice induced by Con A is a newly established experimental liver injury model. Con A, a kind of lectin, binds to sugar residues on the surface of a wide variety of different cell types and stimulates T lymphocytes and macrophages. Con A facilitates cellular immunity in liver tissue, thereby inducing liver injury. Mice with liver injury induced by Con A are therefore, used as experimental models mediated by cellular immunity. T-cell immunity involved in the impairment of hepatocytes mainly mediated by T-cell immunity.

The present study, serum ALT, AST activities, which were the circulating markers of hepatocyte injury, elevated markedly after Con A or BCG+LPS challenge. Pretreatment of FTY 720 could reduce the elevation of serum AST and ALT levels in mice induced by Con A or BCG+LPS. Pretreatment of FTY 720 could reduce the elevation of serum AST and ALT levels in mice induced by Con A or BCG+LPS.

It has been reported that FTY720 prolongs graft survival in various animal models of organ transplantation and other transplantation models. It has been reported that FTY720 prolongs graft survival in various animal models of organ transplantation and other transplantation models. Pretreatment of FTY 720 could reduce the elevation of serum AST and ALT levels in mice induced by Con A or BCG+LPS.

In summary, FTY 720 pretreatment is effective on the effects of FTY 720 on Con A-induced liver injury were closely related. These results confirm our previous speculation, that is, the possible mechanism of the liver-protective effect on the Con A-induced liver injury in Kunming mice.

REFERENCES

1. Luo KX. Hepatitis B Basic Biology and Clinical Science. 2nd ed, Beijing: People’s Health Publishing House 2001: 381-444
2. Zhang XL, Quan QZ, Sun ZQ, Wang YJ, Jiang XL, Wang D, Li WB. Protective effects of cyclosporine A on T-cell dependent ConA-induced liver injury in Kunming mice. World J Gastroenterol 2001; 7: 569-571
3. Kaibori M, Inoue T, Tu W, Oda M, Kwon AH, Kamiyama Y, Okumura T. FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes. Life Sci 2001; 69: 17-26
4. Hrubecová R, Bruck R, Aeed H, Shirin H, Halpern Z. Treatment of concanavalin A-induced hepatitis in mice with low molecular weight heparin. J Hepatol 1999; 31: 834-840
5. Adachi K, Kohara T, Nakano N, Arita M, Chiba K, Mashin T, Sasaki S, Fujita T. Design, Synthesis and structure-activity relationship of 2-substituted-2-amino-1, 2-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995; 5: 853-856
6. Hwang M, Matsushita M, Furukawa Y, Ono K, Okada M, Iwasaki A, Hara M, SasaYama S. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft corona
ty artery disease in a murine model of cardiac transplantation. Circulation 1999; 100: 1322-1329
7. Hozumi Y, Kobayashi E, Miyata M, Fujimura A. Immuno
terapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720. Life Sci 1999; 65: 1739-1745
8. Yan H, Suzuki K, Li XK, Amemiya H, Suzuki S, Hiromitsu K. Immunosuppressive effect of FTY 720 on autoimmune dia
tes models. Transplant Proc 1998; 30: 3436-3437
9. Permppongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, Tsujimura A, Kongkanand A, Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 2002; 98: 167-172
10. Anselmo D, Ameuri FF, Shen XD, Gao F, Katori M, Ke B, Lassman C, Coito AJ, Brinkmann V, Busuttil RW, Kupiec-Weglinski JW, Farmer DG. FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury. Transplant Proc 2002; 34: 1467-1468
11. Kanemaki T, Kitade H, Hiramatsu Y, Kamiyama Y, Okumura T. Stimulation of glycogen degradation by prostaglandin E2 in primary cultured rat hepatocytes. Prostaglandins 1993; 45: 459-474
12. Suzuki S, Li XK, Enosawa S, Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 1996; 89: 518-523
13. Nagahara Y, Enosawa S, IkeKita M, Suzuki S, Shinomiya T. Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology 2000; 48: 75-85
14. Fujino M, Li XK, Guo L, Kitazawa Y, Funeshima N, Fukuda S, Kimura H, Miyashita T, Okuyama T, Amano T, Suzuki S. T-cell apoptosis triggered by FTY720 via mitochondrial pathway. Transplant Proc 2001; 33: 3084-3085
15. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001; 13: 777-784
16. Leist M, Wendel A. A novel mechanism of murine hepatocyte death inducible by concanavalin A. J Hepatol 1996; 25: 948-959
17. Kimura K, Ando K, Ohashi H, Ishikawa T, Kakumu S, Takemura M, Muto Y, MoriwaI H. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int Immunol 1999; 11: 1491-1500
18. Ganttner F, Leist M, Lohse AW, Germann PG, Tieg G. Con
canavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 1995; 21: 190-198
19. Cao Q, Bates R, Pang G, Russell A, Clancy R IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A. Immunol Cell Biol 1998; 76: 542-549
20. Nishikage T, Seki S, Toyaba S, Abo T, Kagata Y, Iwai T, Hiraide H. Inhibition of concanavalin A-induced hepatic injury of mice by bacterial lipopolysaccharide via the induction of IL-6 and the subsequent reduction of IL-4; the cytokine milieu of concanavalin A hepatitis. J Hepatol 1999; 31: 18-26
21. Kato M, Ikeda N, Matsushita E, Kaneko S, Kobayashi K. In
volved in the development of IL-10, an anti-inflammatory cytokine in murine liver injury induced by Concanavalin A. Hepatol Res 2001; 20: 232-243

Edited by Zhu LH and Wang XL Proofread by Ma JY